Get the Stockscreener App
8.74
0.34%
-0.03
Pre-market:
8.72
-0.02
-0.23%
Replimune Group Inc stock is traded at $8.74, with a volume of 1.69M.
It is down -0.34% in the last 24 hours and up +94.22% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
See More
Previous Close:
$8.77
Open:
$8.7
24h Volume:
1.69M
Relative Volume:
0.34
Market Cap:
$687.95M
Revenue:
-
Net Income/Loss:
$-209.96M
P/E Ratio:
-2.7658
EPS:
-3.16
Net Cash Flow:
$-176.27M
1W Performance:
-4.27%
1M Performance:
+94.22%
6M Performance:
+11.34%
1Y Performance:
-18.85%
1-Day Range:
$8.50
$9.00
1-Week Range:
$8.50
$9.37
52-Week Range:
$2.68
$17.00
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Compare REPL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
8.74 | 687.95M | 0 | -209.96M | -176.27M | -3.16 |
|
ARGX
Argen X Se Adr
|
918.53 | 57.24B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.52 | 110.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
201.62 | 42.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
363.92 | 41.68B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
725.34 | 74.02B | 14.25B | 4.58B | 3.88B | 41.77 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| Oct-27-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-20-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-20-25 | Upgrade | Wedbush | Neutral → Outperform |
| Sep-19-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jul-23-25 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| Jul-23-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-23-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-22-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-22-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-22-25 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Apr-17-23 | Resumed | Piper Sandler | Overweight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-17-20 | Initiated | BTIG Research | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-20 | Initiated | Barclays | Overweight |
| Sep-04-19 | Initiated | ROTH Capital | Buy |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| Apr-25-19 | Initiated | Wedbush | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-14-18 | Initiated | JP Morgan | Overweight |
| Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
Smart tools for monitoring Replimune Group Inc.’s price action2025 Key Lessons & Safe Investment Capital Preservation Plans - newser.com
How Replimune Group Inc. stock reacts to global recession fearsTrade Volume Summary & Weekly Stock Breakout Alerts - newser.com
Replimune Group Inc. stock volume spike explainedMarket Trend Review & Weekly Momentum Stock Picks - newser.com
Will Replimune Group Inc. stock deliver shareholder valueWeekly Investment Recap & Fast Entry Momentum Trade Alerts - newser.com
Will Replimune Group Inc. stock deliver consistent dividendsEarnings Beat & Low Drawdown Investment Strategies - newser.com
How to build a custom watchlist for Replimune Group Inc.Weekly Investment Report & Weekly Watchlist of Top Performers - newser.com
How Replimune Group Inc. stock compares to growth peersTrade Entry Report & Safe Entry Trade Signal Reports - newser.com
Using AI based signals to follow Replimune Group Inc.Quarterly Portfolio Summary & AI Enhanced Execution Alerts - newser.com
How to use Fibonacci retracement on Replimune Group Inc.Market Activity Report & Low Risk Growth Stock Ideas - newser.com
What hedge fund activity signals for Replimune Group Inc. stockWeekly Investment Recap & Community Verified Trade Alerts - newser.com
Replimune’s Long-Term Safety Study: A Potential Game-Changer in Oncolytic Immunotherapy - MSN
What risks investors should watch in Replimune Group Inc. stockStock Surge & Breakout Confirmation Trade Signals - newser.com
Cantor Fitzgerald reiterates Overweight rating on Replimune Group stock By Investing.com - Investing.com Australia
Why Replimune Group Inc. stock is a must watch in 2025Market Trend Report & Weekly High Conviction Trade Ideas - newser.com
Replimune reports positive data for melanoma treatment at SITC 2025 By Investing.com - Investing.com Nigeria
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025) - The Manila Times
Replimune reports positive data for melanoma treatment at SITC 2025 - Investing.com India
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.08%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):